• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

TABLE 61Adalimumab cost-effectiveness with changing relapse rates

Relapse rate (SC)Remission lengthICERs (£ per QALY)
sc_relapse only changingBoth relapse rates changing
SCAdalimumab INDAdalimumab MNTSCAdalimumab INDAdalimumab MNT
0.0252.13 yearsBaseline1,133,765Baseline1,112,324
0.051.24 yearsBaseline532,789Baseline520,769
0.075314 daysBaseline333,906Baseline322,790
0.1240 daysBaseline234,236Baseline224,302
0.125193 daysBaseline174,035Baseline165,702
0.15161 daysBaseline134,504Baseline122,261
0.175137 daysBaseline106,350Baseline98,714
0.2119 daysBaseline85,136Baseline77,959
0.225105 daysBaseline68,862Baseline61,774
0.2594 daysBaseline55,883Baseline48,849
0.27584 daysBaseline45,445Baseline38,320
0.376 daysBaseline36,710Baseline29,663
0.32569 daysBaseline29,397Baseline22,308
0.3564 daysBaseline23,149Baseline16,007
0.37559 daysBaseline17,807Baseline10,564
0.454 daysBaseline13,164Baseline5852
0.42550 daysBaseline9121Baseline1692
0.4547 daysBaseline5543BaselineDominates
0.47544 daysBaseline2385BaselineDominates
0.541 daysDominatesBaselineDominates

Bold values indicate cost-effective option at £30,000 per QALY.

– denotes that an option is dominated by one or more options.

From: 4, Assessment of cost-effectiveness

Cover of A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease
A Systematic Review and Economic Evaluation of the Use of Tumour Necrosis Factor-Alpha (TNF-α) Inhibitors, Adalimumab and Infliximab, for Crohn's Disease.
Health Technology Assessment, No. 15.6.
Dretzke J, Edlin R, Round J, et al.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.